Teva Pharmaceutical Industries Ltd (TEVA) Expected to Post Earnings of $0.53 Per Share

Brokerages forecast that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will report $0.53 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Teva Pharmaceutical Industries’ earnings. The lowest EPS estimate is $0.45 and the highest is $0.57. Teva Pharmaceutical Industries reported earnings of $0.93 per share during the same quarter last year, which would suggest a negative year over year growth rate of 43%. The firm is expected to issue its next quarterly earnings report on Thursday, February 14th.

According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full-year earnings of $2.80 per share for the current financial year, with EPS estimates ranging from $2.71 to $3.03. For the next fiscal year, analysts anticipate that the company will post earnings of $2.83 per share, with EPS estimates ranging from $2.65 to $3.10. Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, November 1st. The company reported $0.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.53 by $0.11. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.69%. The company had revenue of $4.53 billion during the quarter, compared to the consensus estimate of $4.54 billion. During the same period in the prior year, the firm earned $1.00 earnings per share. Teva Pharmaceutical Industries’s revenue was down 19.4% on a year-over-year basis.

TEVA has been the topic of a number of recent research reports. Goldman Sachs Group upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “conviction-buy” rating and set a $30.00 price objective on the stock in a report on Monday, October 1st. Credit Suisse Group cut shares of Teva Pharmaceutical Industries from an “outperform” rating to a “neutral” rating and cut their price objective for the stock from $25.00 to $23.00 in a report on Friday, September 7th. Leerink Swann upgraded shares of Teva Pharmaceutical Industries from an “underperform” rating to a “market perform” rating and upped their price objective for the stock from $16.00 to $24.00 in a report on Monday, October 1st. Cantor Fitzgerald set a $25.00 price objective on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Friday, September 14th. Finally, Mizuho upped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $29.00 and gave the stock a “buy” rating in a report on Monday, September 17th. Five research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Teva Pharmaceutical Industries has a consensus rating of “Hold” and a consensus price target of $21.26.

In related news, VP Richard Daniell sold 2,488 shares of the firm’s stock in a transaction that occurred on Tuesday, September 18th. The shares were sold at an average price of $23.69, for a total value of $58,940.72. Following the sale, the vice president now owns 2,488 shares in the company, valued at $58,940.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Deborah A. Griffin sold 2,376 shares of the firm’s stock in a transaction that occurred on Tuesday, September 18th. The stock was sold at an average price of $23.71, for a total transaction of $56,334.96. Following the completion of the sale, the insider now owns 2,376 shares in the company, valued at approximately $56,334.96. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,350 shares of company stock worth $239,430. Corporate insiders own 0.43% of the company’s stock.

A number of hedge funds have recently modified their holdings of TEVA. PointState Capital LP purchased a new stake in Teva Pharmaceutical Industries in the second quarter worth approximately $161,826,000. Point72 Asset Management L.P. purchased a new stake in Teva Pharmaceutical Industries in the second quarter worth approximately $90,746,000. Renaissance Technologies LLC boosted its holdings in Teva Pharmaceutical Industries by 348.1% in the second quarter. Renaissance Technologies LLC now owns 4,036,863 shares of the company’s stock worth $98,177,000 after purchasing an additional 3,135,900 shares during the last quarter. Beck Mack & Oliver LLC purchased a new stake in Teva Pharmaceutical Industries in the third quarter worth approximately $64,484,000. Finally, Caisse DE Depot ET Placement DU Quebec boosted its holdings in Teva Pharmaceutical Industries by 116.1% in the second quarter. Caisse DE Depot ET Placement DU Quebec now owns 2,354,508 shares of the company’s stock worth $57,262,000 after purchasing an additional 1,264,900 shares during the last quarter. Institutional investors own 64.73% of the company’s stock.

TEVA traded down $0.41 during midday trading on Friday, reaching $22.59. The company’s stock had a trading volume of 11,391,865 shares, compared to its average volume of 10,241,511. The stock has a market cap of $22.97 billion, a PE ratio of 5.75, a price-to-earnings-growth ratio of 1.86 and a beta of 0.77. The company has a debt-to-equity ratio of 1.86, a quick ratio of 0.69 and a current ratio of 1.03. Teva Pharmaceutical Industries has a 1 year low of $10.91 and a 1 year high of $25.96.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Read More: What are the economic characteristics of a bear market?

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply